Based on our results, siRNA-mediated knockdown of RUNX3 resulted in a significant decrease in sensitivity to anti-cancer drug in p53-proficient cells but not in p53-deficient cells, suggesting that there could exist a functional interaction between RUNX3 and p53 in response to DNA damage. The gene discussed is TP53; the disease is cancer.